This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
by Kanishka Das
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
pharmaceuticals
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
pharmaceuticals
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
by Kinjel Shah
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
pharmaceuticals
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
by Kinjel Shah
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
pharmaceuticals
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
by Zacks Equity Research
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
biotechnology biotechs medical pharmaceuticals
Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia
by Zacks Equity Research
Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.
alt-energy computers etfs pharmaceuticals semiconductor tech-stocks
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
biotechnology biotechs medical pharmaceuticals
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for Nov. 13
by Zacks Equity Research
AMRK, ALVO and GPK have been added to the Zacks Rank #5 (Strong Sell) List on Nov. 13, 2025.
pharmaceuticals